On August 5, Bruker rose 5.05% in regular trading, trading at $52.835/share, with turnover of $185 million. The stock partially recovered from the prior session's steep 18.72% decline triggered by its Q2 earnings report.

On the news front, Bruker reported Q2 adjusted EPS of $0.49, beating the consensus estimate of $0.39 by 25.64% and representing a 53% year-over-year increase. However, quarterly revenue of $838.5 million fell short of the $853.6 million estimate. The company also cut its fiscal year revenue guidance to $3.54-$3.57 billion from the prior $3.57-$3.60 billion range. While the revenue miss and lowered outlook drove the initial selloff, the significantly stronger-than-expected profitability may have attracted buyers at depressed levels.

Within the Life Sciences Tools and Services sector, Charles River Laboratories rose 10.96%, Danaher gained 1.82%, Thermo Fisher Scientific gained 1.86%, Waters rose 0.36%, while Illumina fell 2.18%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)